Showing results (141-150 of 241) with videos related to

Sort By:
Pageof 25
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancerOladapo O Yeku, Minal Barve, Winston W Tan, et al.
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing CancersTimothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Pageof 25